AR121832A1 - KIF18A INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES - Google Patents
KIF18A INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASESInfo
- Publication number
- AR121832A1 AR121832A1 ARP210100975A ARP210100975A AR121832A1 AR 121832 A1 AR121832 A1 AR 121832A1 AR P210100975 A ARP210100975 A AR P210100975A AR P210100975 A ARP210100975 A AR P210100975A AR 121832 A1 AR121832 A1 AR 121832A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- kif18a
- tumor
- methods
- neoplastic disease
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se proporcionan métodos para tratar a un sujeto que tiene una enfermedad neoplásica, que comprenden administrar al sujeto un inhibidor de KIF18a en una cantidad eficaz para tratar la enfermedad neoplásica y una enfermedad neoplásica en un sujeto. También se proporcionan métodos para inducir o aumentar la regresión tumoral en un sujeto con un tumor y métodos para reducir el crecimiento tumoral o del cáncer en un sujeto. En aspectos de ejemplo, el método comprende administrar al sujeto un inhibidor de KIF18A. En el presente documento también se proporcionan métodos para inducir o aumentar la muerte de células tumorales o cancerosas en un sujeto que comprenden administrar al sujeto un inhibidor de KIF18A. Ventajosamente, los inhibidores de KIF18A tratan selectivamente la enfermedad neoplásica, inducen o aumentan la regresión tumoral y/o inducen o aumentan la muerte de células tumorales o cancerosas sin una toxicidad manifiesta para las células somáticas normales.Provided herein are methods of treating a subject having a neoplastic disease, comprising administering to the subject a KIF18a inhibitor in an amount effective to treat the neoplastic disease and a neoplastic disease in a subject. Also provided are methods of inducing or enhancing tumor regression in a subject with a tumor and methods of reducing tumor or cancer growth in a subject. In exemplary aspects, the method comprises administering to the subject a KIF18A inhibitor. Also provided herein are methods of inducing or enhancing tumor or cancer cell death in a subject comprising administering to the subject an inhibitor of KIF18A. Advantageously, KIF18A inhibitors selectively treat neoplastic disease, induce or enhance tumor regression, and/or induce or enhance tumor or cancer cell death without overt toxicity to normal somatic cells.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009637P | 2020-04-14 | 2020-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121832A1 true AR121832A1 (en) | 2022-07-13 |
Family
ID=83218585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100975A AR121832A1 (en) | 2020-04-14 | 2021-04-13 | KIF18A INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR121832A1 (en) |
-
2021
- 2021-04-13 AR ARP210100975A patent/AR121832A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002808A1 (en) | Kif18a inhibitors for the treatment of neoplastic diseases | |
| CL2021001575A1 (en) | Substituted pyrazolopyrimidines and substituted purines and their use as inhibitors of ubiquitin-specific processing protease 1 (usp1) | |
| DOP2020000209A (en) | METHODS TO TREAT CANCERS AND ENHANCE THE EFFECTIVENESS OF THERAPEUTIC AGENTS FOR REDIRECTING T CELLS | |
| ECSP17072756A (en) | FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) / PROGRAMMED DEATH 1 (PD-1) COMBINATION THERAPY FOR THE TREATMENT OF CANCER. | |
| CL2020002146A1 (en) | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer. | |
| MX2020009773A (en) | Combination therapy. | |
| UY38263A (en) | PURINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| ES2422605T3 (en) | Antibody against klotho-beta for use in the treatment of tumors, cancer or cell proliferative disorders | |
| AR023400A1 (en) | METHODS TO INDUCE DEATH OF CANCER CELLS AND TUMORS REGRESSION | |
| PE20211961A1 (en) | COMBINATION THERAPY OF RADIOIMMUNOCONJUGATES WITH DAMAGE INHIBITORS AND DNA REPAIRS | |
| BRPI0517135A (en) | compositions and methods for treating neoplastic diseases | |
| CL2021002533A1 (en) | Compositions and methods for treating diseases or disorders associated with kras | |
| MX2020001727A (en) | Combination therapy. | |
| BR112023000687A2 (en) | METHODS AND COMBINATIONS OF KAT6 INHIBITORS FOR THE TREATMENT OF CANCER | |
| CL2020002544A1 (en) | Ret inhibitor for use in treating cancer that has a ret alteration | |
| MX2018012511A (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors. | |
| AR121566A1 (en) | A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA DIRECTED THERAPY AND USES THEREOF | |
| BR112023005160A2 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| UY33790A (en) | COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND MEK INHIBITOR. | |
| CO2021015130A2 (en) | bnip3 peptides for the treatment of reperfusion injury | |
| AR118585A1 (en) | METHODS TO TREAT PORTOPULMONARY HYPERTENSION | |
| CL2023000857A1 (en) | Line-1 inhibitors to treat the disease | |
| CO2023017973A2 (en) | Transforming Growth Factor βeta Ligand Traps for Disease Treatment | |
| AR121832A1 (en) | KIF18A INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | |
| CL2023003090A1 (en) | Combinations of therapeutic compositions and uses to treat cancers |